News
LimFlow news archives.
LimFlow Expands Senior Management Team and Opens Silicon Valley Office
LimFlow Expands Senior Management Team and Opens Silicon Valley Office
LimFlow Receives FDA Approval for U.S. Feasibility Study of Minimally-Invasive Technology Designed to Restore Perfusion in “No Option” Critical Limb Ischemia Patients
LimFlow Receives FDA Approval for U.S. Feasibility Study of Minimally-Invasive Technology Designed to Restore Perfusion in “No Option” Critical Limb Ischemia Patients
LimFlow Receives CE Mark for Purely Percutaneous Critical Limb Ischemia (CLI) Technology Designed to Restore Perfusion for “No Option” Patients
LimFlow Receives CE Mark for Purely Percutaneous Critical Limb Ischemia (CLI) Technology Designed to Restore Perfusion for “No Option” Patients
LimFlow Announces Presentation of the LimFlow Procedure at a Dedicated Symposium During the Leipzig Interventional Course, LINC 2015 – January 27-30, 2015
LimFlow Announces Presentation of the LimFlow Procedure at a Dedicated Symposium During the Leipzig Interventional Course, LINC 2015 – January 27-30, 2015
Dresden Germany 15 December 2014 — LimFlow today announced that Drs. Andrej Schmidt and Jihad Mustapha will be chairing a session on the LimFlow procedure for treating Critical Limb Ischemia at the upcoming Leipzig Interventional Course or LINC on Tuesday 27 January 2015 starting at 16:00 CET (www.leipzig-interventional-course.com) .
Download a schedule of the talks.
About LimFlow GmbH
LimFlow is a private, venture-backed medical device company offering a novel therapeutic to treating Critical Limb Ischemia. LimFlow is enrolling patients into its feasibility clinical study using its patented Percutaneous Deep Vein Arterialization in Singapore and Leipzig Germany with its CE Mark trial to being in early 2015.
LimFlow Announces the Closing of Series A Financing
LimFlow Announces the Closing of Series A Financing
Dresden Germany 30 September, 2014 — LimFlow today announced that it has closed its Series A financing with a major Family Fund leading the round. The terms and amount were not discussed.
About LimFlow GmbH
LimFlow is a private, venture-backed medical device company offering a novel therapeutic to treating Critical Limb Ischemia. LimFlow is enrolling patients into its feasibility clinical study using its patented Percutaneous Deep Vein Arterialization in Singapore and Leipzig Germany with its CE Mark trial to being in early 2015.
For more information about LimFlow, please visit www.LimFlow.com. The LimFlow System is not approved for sale in Europe and is not approved for sale or investigational use in the United States. For additional information, contact Tim Lenihan, CEO, LimFlow GmbH ; [email protected] or +49 173 356 8405.